Highlights Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 13/02/2026			5-day change	1st Jan Change
58.23 ^CNY	-0.87%		+1.36%	-2.25%

02-16	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 72.38 Yuan From 78.21 Yuan, Keeps at Buy	MT
02-11	Jiangsu Hengrui Medicine Gets Priority Review Approval for Colorectal Cancer Drug	MT

Highlights

02-10	Kailera Therapeutics & Hengrui Pharma report positive topline data from phase 2 obesity trial of oral ribupatide	RE
02-10	Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide	CI
02-09	Jiangsu Hengrui Medicine Gets Breakthrough Therapy Designation for Cancer Drug	MT
02-06	Hengrui Pharmaceuticals' Gout Drug Application Accepted by Regulators	MT
01-27	Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials	MT
01-22	Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs	MT
01-21	Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs	MT
01-21	Hengrui Pharmaceuticals Gets Nod to Trial Two Tumor Drugs	MT
01-13	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
01-13	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT
01-08	Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug	MT
01-07	Jiangsu Hengrui Pharmaceuticals says unit got notice from NMPA for retlirafusp alfa injection	RE
01-06	Hengrui Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Clinical Trials	MT
01-06	Hengrui Pharmaceuticals Gets Approval for Combined Obesity Drug Trials	MT
01-04	Tranche Update on Jiangsu Hengrui Pharmaceuticals Co.,Ltd's Equity Buyback Plan announced on August 20, 2025.	CI
12-30	Hengrui Pharma Gets Nod to Trial Six Drugs	MT
12-30	Hengrui Pharma Gets Nod to Trial HRS-6257 Tablets	MT
12-29	Hengrui Pharmaceuticals Licenses Kidney Drug to Hansoh Pharma in Related-Party Deal	MT
12-28	Jiangsu Hengrui Pharmaceuticals Co.,Ltd Enters into A License Agreement	CI
12-15	Hengrui Medicine's Unit Gets Nod to Trial Tumor Drug	MT
12-15	Hengrui Medicine's Unit Gets Nod to Trial RSS0343 Tablets	MT
12-15	Hengrui Medicine's Unit Gets Nod to Trial HRS9531 Injection	MT
12-08	Jiangsu Hengrui Medicine Gets Inclusion in China's Medical Insurance Catalog	MT
12-03	Hengrui Medicine Gets Regulatory Acceptance for Anesthetic Marketing Application	MT
11-28	Hengrui Medicine Gets China Approval for Multiple Drug Trials	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

600276

CNE0000014W7

Pharmaceuticals

Highlights

Filters